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Abstract: The current study aimed to develop pH-responsive cisplatin-loaded liposomes (CDDP@PLs)
via the thin film hydration method. Formulations with varied ratios of dioleoyl phosphatidylethanolamine
(DOPE) to cholesteryl hemisuccinate (CHEMS) were investigated to obtain the optimal particle size,
zeta potential, entrapment efficiency, in vitro release profile, and stability. The particle size of the
CDDP@PLs was in the range of 153.2 ± 3.08–206.4 ± 2.26 nm, zeta potential was −17.8 ± 1.26 to
−24.6 ± 1.72, and PDI displayed an acceptable size distribution. Transmission electron microscopy
revealed a spherical shape with ~200 nm size. Fourier transform infrared spectroscopic analysis
showed the physicochemical stability of CDDP@PLs, and differential scanning calorimetry analysis
showed the loss of the crystalline nature of cisplatin in liposomes. In vitro release study of CDDP@PLs
at pH 7.4 depicted the lower release rate of cisplatin (less than 40%), and at a pH of 6.5, an almost
65% release rate was achieved compared to the release rate at pH 5.5 (more than 80%) showing the
tumor-specific drug release. The cytotoxicity study showed the improved cytotoxicity of CDDP@PLs
compared to cisplatin solution in MDA-MB-231 and SK-OV-3 cell lines, and fluorescence microscopy
also showed enhanced cellular internalization. The acute toxicity study showed the safety and
biocompatibility of the developed carrier system for the potential delivery of chemotherapeutic
agents. These studies suggest that CDDP@PLs could be utilized as an efficient delivery system for the
enhancement of therapeutic efficacy and to minimize the side effects of chemotherapy by releasing
cisplatin at the tumor site.

iations.
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1. Introduction
Cancer remains one of the leading causes of mortality, and more than eight million
people die due to cancer each year [1]. The World Health Organization estimates that the
number of new cancer cases might increase from 11.3 million in 2007 to approximately
15.5 million in 2030. Chemotherapy is one of the treatment options for cancer in addition to
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surgery and radiotherapy. The delivery of chemotherapeutic agents has low concentration
at the tumor site, inevitable distribution, and widespread side effects, which limits its
clinical applications. Therefore, the targeted delivery of chemotherapeutic agents has
become a focus of scientific research to deliver the drug at the site of action [2,3].
In recent years, nanotechnology has become a scientific buzzword for drug delivery
research. Nanoparticulate drug delivery systems are attributed to nano-sized (10–200 nm)
drug delivery systems that may facilitate the targeted delivery of a drug at the tumor site.
The targeting of these therapeutics agent(s) has bought a massive revolution in cancer
chemotherapy via the effective delivery of cytotoxic agents at the tumor site [4].
Vesicular drug delivery systems are highly ordered assemblies consisting of one or
more concentric bilayers formed by the self-assembly of amphiphiles upon hydration [5].
Among the vesicular drug delivery system, liposomes have been extensively investigated
as a carrier of choice for the delivery of both hydrophilic and lipophilic therapeutic agent(s).
Liposomes are bilayered vesicles of phospholipids enclosing a hydrophilic core [6]. Liposomes have shown promising results in the delivery of chemotherapeutics to the site of
action as they resemble cell-membrane structure and display biocompatibility, low immunogenicity, enhancement of half-life, safety and efficacy. However, conventional liposomes
can only achieve delivery to the initially targeted organs/tissues, and there is still a certain
inevitable distribution and damage to the normal organs/tissues [7]. To overcome the
aforementioned limitations of conventional liposomes, stimuli-responsive liposomes have
been fabricated.
Stimuli-responsive drug delivery systems are those agent(s) that undergo a physical/chemical change in response to a stimulus. The field of stimuli-responsive drug delivery
systems has investigated the concept of a pH-responsive drug delivery platform(s) [1,8].
The effectiveness of pH-responsive drug delivery systems is based on the fact that they can
exploit well-characterized pH differences between blood and pathological conditions (such
as infection, inflammation and cancer), and also between certain intracellular compartments
such as cytosol, endosome, and lysosomes in our body [9].
Cisplatin (CDDP), chemically known as cis-diamminedicholoroplatinum (II) anticancer agent, is used in the treatment of various malignancies such as breast, ovarian,
testicular, cervical, bladder, head and neck, brain and non-small- cell lung cancers [10,11].
It acts as DNA cross-linking agent and interferes with the replication and transcription of
DNA synthesis. It is the most widely used anticancer agent due to its broader efficacy in the
treatment of various types of tumors [12]. The broader applications of CDDP are limited by
resistance, rapid inactivation, and severe side effects (nephrotoxicity, neurotoxicity, and
myelotoxicity) [13]. Therefore, to overcome these CDDP-related issues, efforts have been
made to develop a CDDP delivery system by using pH-responsive liposomes.
pH-responsive drug delivery platforms offer the potential of enhancing the therapeutic
efficacy and minimizing the side effects of chemotherapy by releasing the encapsulated
drug at the site of action [14]. The lower pH is a hallmark of tumor/malignancy caused
due to excessive metabolite (lactic acid, carbon dioxide, increased expression, and activity
of vacuolar-type (V-type) H+-ATPases (proton pumps) [15].
The delivery of a chemotherapeutic agent to the tumor site by the pH-responsive
liposomes presents an efficient means of overcoming the problem of targeted drug delivery
to the tumor site. Fan, Y. et al., 2017, [2] and Leite, E.A. et al., 2012, [16] reported similar
studies that showed improvements of the pH-responsive targetability of liposomes at the
tumor site. In the present study, pH-responsive lipid(s) were used that protonate at lowered
pH, resulting in the rapid destabilization of the carrier and the release of the drug in the
acidic tumor microenvironment [17,18].
2. Materials and Methods
2.1. Materials
Cisplatin was received as a kind gift sample from Pharmedic Laboratories Pvt (Ltd.)
Pakistan. Dioleoyl phosphatidylethanolamine (DOPE) was obtained from Avanti Polar
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Lipids, Inc, Alabaster, AL, USA, cholesteryl hemisuccinate (CHEMS) from Avanti Polar Lipids, Inc., Alabaster, AL, USA, and DSPE-PEG2000 was a kind gift from LIPOID,
Steinhausen, Switzerland. 4, 6-diamidino-2-phenylindole dihydrochloride (DAPI) was
purchased from Vector Laboratories, Inc., Burlingame, CA, USA. Fluorescein isothiocyanate
(FITC) and paraformaldehyde were procured from Sigma-Aldrich, St. Louis, MO, USA.
Dulbecco modified eagle medium (DMEM) was purchased from Thermo Fisher Scientific
Corporation, San Francisco, CA, USA. Polycarbonate-membrane-based mini extruders
(Nano-sizer Mini® ) were purchased from T&T scientific, Knoxville, TN, USA. Chloroform
and methanol were of analytical grade and were purchased from Sigma-Aldrich, Steinheim am Albuch, Germany. Distilled water was freshly prepared by the distillation plant
(IRMECO® , Schwarzenbek, Lütjensee, Germany).
2.2. Preparation of Cisplatin Loaded pH-Responsive Liposomes
Cisplatin-loaded pH-responsive liposomes (CDDP@PLs) were prepared via the thinfilm hydration method. Briefly, DOPE, CHEMS and DSPE-PEG2000 were weighed (Table 1)
and dissolved in a 15 mL solvent mixture of chloroform and methanol (2:1, v/v) in a round
bottom flask. The organic solvent was removed using a rotary evaporator (Heidolph,
Schwabach, Germany) under reduced pressure at 75 rpm and 60 ± 2 ◦ C for 3 h. The flask
was removed and kept overnight in an oven to remove the solvent residues completely.
Then, the lipid film was hydrated using cisplatin solution in phosphate-buffered saline
(pH 7.4) (5.0 mg/10 mL). The resultant liposomal suspension was vortexed and sonicated
(ELMA, E-30 H, Pforzheim, Germany) for about 10 min (at 25 ◦ C and an amplitude of
30%), and then extruded through polycarbonate-membrane-based mini extruders (100 nm,
Nano-sizer Mini® , T&T scientific corporations, Knoxville, TN, USA) to obtain the liposomes
for further analysis [19].
Table 1. Physicochemical characteristics of CDDP@PLs.

Code

Lipid Mixture
Ratio (DOPE:
CHEMS:
DSPE:PEG2000 )

Lipid Mixture
Weight (mg)
DOPE: CHEMS:
DSPE-PEG2000

Cisplatin (mg)

Particle Size
(nm)

PDI

Zeta Potential
(mV)

(%) E.E

PL1
PL2
PL3
PL4
PL5

45:50:05
50:45:05
55:40:05
60:35:05
65:30:05

33.48:24.33:14.02
37.20:21.90:14.02
40.92:19.46:14.02
44.64:17.03:14.02
48.36:14.60:14.02

5.0
5.0
5.0
5.0
5.0

206.4 ± 2.26
194.3 ± 2.21
191.2 ± 1.67
171.9 ± 2.26
153.2 ± 3.08

0.417 ± 0.008
0.422 ± 0.010
0.386 ± 0.009
0.371 ± 0.011
0.261 ± 0.007

−24.6 ± 1.72
−22.8 ± 2.01
−22.5 ± 0.38
−20.2 ± 2.69
−17.8 ± 1.26

69.47 ± 1.23
65.52 ± 2.14
61.23 ± 1.98
52.19 ± 1.45
47.25 ± 1.21

2.3. Physicochemical Characterization of Liposomes
2.3.1. Particle Size, Polydispersity Index (PDI) and Zeta Potential
The particle size, PDI and zeta potential of the developed CDDP@PLs were analyzed using Zeta Sizer-ZS90 (Malvern, Worcestershire, UK). The dynamic light scattering
technique was used for the determination of particle size, PDI and zeta potential. The
measurement was performed at 25 ◦ C and in triplicate for each sample [20].
2.3.2. Entrapment Efficiency
The entrapment efficiency (E.E) of the CDDP@PLs was determined by the indirect
method. Briefly, the liposomes were centrifuged by ultra-centrifugation (Sigma-Aldrich,
Darmstadt, Germany) at 12,000 rpm for 40 min. The supernatant was collected for the
quantification of the unentrapped drug and the process was repeated in triplicate for
each sample. The drug was then estimated by taking absorbance through a UV/Visible
spectrophotometer (IRMECO, 2020, Schwarzenbek, Lütjensee, Germany) [21]. The E.E was
determined by the following formula:
(%) E.E = (Total amount of drug used-Amount of unentrapped drug)/(Total amount of drug used) × 100

(1)
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2.3.3. Transmission Electron Microscopy (TEM)
The surface morphology of the CDDP@PLs was determined via transmission electron
microscopy (JEOL, 2100, Jeol, Akishima, Tokyo, Japan). The sample was applied on the
coated side of the grid and was allowed to settle for 5 min. The grids were then blotted on
filter paper and stained with a 1% aqueous solution of phosphotungstic acid and kept for
3 min. The grids were then rinsed with distilled water to wash off the excess stain and then
dried at room temperature. The grids were then placed in a sample inlet chamber of TEM
and observed, and suitable images were taken at different magnifications [22].
2.3.4. Fourier Transform Infrared (FTIR) Spectroscopic Analysis
Fourier transform infrared spectroscopic analysis is an efficient and accurate technique
to find any interaction among the formulation components. FTIR spectra of cisplatin, DOPE,
CHEMS, DSPE-PEG2000 , and CDDP@PLs were measured by using ATR-FTIR (Bruker,
Tensor 27 Series, Berlin, Germany) in the range of 400 cm−1 to 4000 cm−1 [23].
2.3.5. Differential Scanning Calorimetric (DSC) Analysis
DSC analysis was performed to evaluate any possible interaction and to check the
physical state of cisplatin in the developed formulation. The differential scanning calorimetric (DSC) analysis of cisplatin, CHEMS, DOPE, DSPE-PEG2000 and CDDP@PLs was
analyzed via a differential scanning calorimeter (DSC-250, TA instruments, New Castle,
DE, USA). In the analysis, the calibration was carried out by using indium for the source
of temperature and heat flow. Samples were placed on one pan, and another aluminum
pan was used as a reference. The samples were then heated over the temperature range of
25–400 ◦ C [24].
2.3.6. In Vitro Release and Kinetic Modeling
The in vitro release study of CDDP@PLs was performed in USP type-II dissolution
apparatus (paddle) using the dialysis bag method. The dialysis membrane of MWCO
12–14 kDa was used. The drug release study was performed for all five formulations in
phosphate-buffered saline (PBS) (pH 7.4, 6.5 and 5.5) in dialysis bags at 37 ± 0.5 ◦ C and
70 rpm. All the formulations contained 5 mg of cisplatin. At selected time intervals, 3 mL
of release media was collected and replenished with an equal volume of fresh media.
The amount of cisplatin released was determined using a UV/Visible spectrophotometer
at 210 nm [25]. The data were applied to the kinetic modeling using Zero order, First
order, Higuchi, and Korsmeyer–Peppas models [26]. The values of the regression coefficient (R2 ) and release exponent (n) were analyzed for the mechanism of drug release
from CDDP@PLs.
2.4. Cell Lines and Cell Culture
2.4.1. Cell Lines
Human breast adenocarcinoma cancer cell lines (MDA-MB-231) and human ovarian
cancer cell lines (SK-OV-3) obtained from American Type Culture Collection (ATCC) (Manassas, VA, USA) were cultured in a flask containing Dulbecco’s modified eagle medium
(DMEM) supplemented with 10% fetal bovine serum (FBS) and antibiotics (100 IU/mL
streptomycin). The cells were stored in the incubator with a supply of 5% CO2 and at 37 ◦ C,
and passage was performed after 80% confluence.
2.4.2. Cytotoxicity Study
The cytotoxicity studies were performed on MDA-MB-231 and SK-OV-3 cells via
an MTS (5-(3-carboxymethoxyphenyl)-2-(4,5-dimethyl-thiazolyl)-3-(4-sulfophenyl) tetrazolium assay (colorimetric technique). An MTS assay is based on the conversion of tetrazolium salt into a colored formazan by the mitochondria activity of living cells. The amount
of formazan depends on the viable cell count in the culture and is measured with a spectrophotometer. Cells previously cultured were seeded in each well of 96-well plates. After
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24 h of incubation, cells were treated with cisplatin solution and liposomal formulation at
a cisplatin concentration range of 0.078 to 10 µg/mL. The absorbance of the solution was
measured on a microplate reader (BioTek, Winooski, VT, USA) at 490 nm [27].
2.4.3. Cell Uptake Study
Fluorescence Microscopy
The qualitative cellular uptake study was performed using a confocal scanning laser
microscope. Cells (5000) were seeded on coverslips in a 6-well plate containing 2 µL of
media for two hours. Cells were placed in the incubator with the supply of CO2 and
allowed to adhere for 24 h. Cells were treated with CDDP@PLs containing fluorescent
dye FITC and free cisplatin, and after 4 h of incubation, cells were collected and washed
three times with PBS (pH 7.4) and fixed with PBS containing 4% paraformaldehyde for
30 min at room temperature. Cells were washed again using PBS and then stained with
DAPI (50 µg/mL) for 15 min. Cells were washed again and then mounted on Fisherbrand
Superfrost® microscope slides with Fluoromount G® mounting buffer (Southern Biotech,
Birmingham, AL, USA) for analysis via a confocal microscope (Olympus CX41) [28].
2.5. Stability Studies
Stability studies are very important in the development of liposomal formulations. For
the approval and acceptance of pharmaceutical products, the continuation of the product’s
safety, efficacy and quality are considered during their shelf life. The particle size, PDI and
zeta potential with time are workable indicators of the stability of the liposomal suspension.
The stability of the developed liposomes was carried out according to the international
conference on harmonization (ICH) guidelines. The particle size analysis was measured,
and 5 mL of each formulation was stored at 2–8 ◦ C, room temperature (25 ± 2 ◦ C), and
elevated temperature (37 ± 2 ◦ C) for three months. The particle size, PDI and zeta potential
were then determined for the stability of the CDDP@PLs [28,29].
2.6. Acute Toxicity Study
Acute toxicity studies were performed according to the Organization for Economic
Cooperation and Development (OECD) guidelines. The acute toxicity study was used to
determine the safety and compatibility of the developed liposomal formulation components [30]. The main objective of the study was to determine the toxicity of the liposomal
components and their distribution within the body. Twelve healthy albino mice were
selected, acclimatized, efficiently monitored, divided into two groups, and kept in separate
cages. The approval of the study was taken from the Pharmacy Animal Ethics Committee
(PAEC), Institutional Ethical Committee under Reference No: 17-2020/PAEC. Distilled
water was administered to the control group, and liposomal components were administered
via a parenteral route to the test group at a single dose of 2000 mg/kg. Various parameters
were properly monitored, such as physical observation, mortality rate, and food and water
consumption. After two weeks, blood samples were collected from albino mice for blood
biochemistry, and then the mice were sacrificed for histopathological examination of vital
organs [31].
2.7. Statistical Analysis
GraphPad Prism 8 (GraphPad Software, San Diego, CA, USA), OriginPro 9.0, and
Microsoft Excel were used for the statistical analysis of the data. All the experiments
were carried out in triplicate and were expressed as the mean ± standard deviation (SD).
One-way ANOVA followed by Post hoc Tukey analysis was applied to determine the
statistical differences.
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3.1.4. Fourier Transform Infrared (FTIR) Spectroscopic Analysis
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derivative). By increasing the concentration of CHEMS (in PL1, PL2 and PL3), the amount
of cisplatin released from CDDP@PLs was decreased. This decrease in the release rate was
observed with a higher concentration of CHEMS and optimum DOPE concentration,
which might be due to slower diffusion of cisplatin from the lipid bilayer. The maximum
release of 87% was observed by PL3 with optimum DOPE concentration, and above
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Formulation
Code
PL1
PL2

pH
7.4
6.5
5.5
7.4

tive). By increasing the concentration of CHEMS (in PL1, PL2 and PL3), the amount of
Zero
Orderfrom CDDP@PLs
First Order was decreased.
Higuchi Model
Korsmeyer–Peppas
cisplatin
released
This decrease
in the release rateModel
was
2
2
2
R a higher concentration
R
R optimum DOPE
R2concentration,N
observed with
of CHEMS and
which
might be 0.0072
due to slower diffusion
the lipid bilayer.
The maximum0.279
release
0.1690of cisplatin from
0.8103
0.9898
of 87% was
observed by PL3
with optimum DOPE
and above this
level
0.0837
0.4866
0.8409 concentration,
0.9690
0.309
(in PL4 and
PL5),
the
release
was
further
decreased
with
the
increased
concentration
0.5912
0.9015
0.9823
0.9949
0.426 of
DOPE [42]. The values of kinetic modeling (at pH 7.4, 6.5 and 5.5) showed that the cisplatin
0.0728
0.2674
0.8440
0.9910
0.279
release from the liposomes was best fit to a Korsmeyer–Peppas model, which is usually
followed by liposomes [43]. The value of release exponent for the liposomes at pH 7.4
and 6.5 were less than 0.45, indicating the mechanism of drug release by Fickian diffusion,
whereas in the case of a pH of 5.5, all the formulations showed the same mechanism, except
for in the case of PL2 and PL3, which were greater than 0.45, indicating the mechanism of
non-Fickian diffusion or anomalous behavior drug release (Table 2).
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Table 2. Kinetic modeling of in vitro release profile of CDDP@PLs at pH 7.4, 6.5 and 5.5.
Zero Order

First Order

Higuchi Model

R2

R2

R2

R2

N

7.4
6.5
5.5

0.0072
0.0837
0.5912

0.1690
0.4866
0.9015

0.8103
0.8409
0.9823

0.9898
0.9690
0.9949

0.279
0.309
0.426

PL2

7.4
6.5
5.5

0.0728
0.0778
0.6863

0.2674
0.4938
0.9278

0.8440
0.8405
0.9915

0.9910
0.9731
0.9940

0.279
0.307
0.464

PL3

7.4
6.5
5.5

0.0734
0.1466
0.6707

0.1488
0.5724
0.9242

0.7930
0.8670
0.9904

0.9952
0.9823
0.9943

0.271
0.316
0.456

PL4

7.4
6.5
5.5

0.0297
0.3215
0.5821

0.2282
0.6595
0.8919

0.8335
0.9233
0.9803

0.9968
0.9910
0.9946

0.289
0.349
0.421

PL5

7.4
6.5
5.5

0.0759
0.3830
0.4436

0.2496
0.6810
0.8238

0.8439
0.9375
0.9582

0.9936
0.9900
0.9988

0.294
0.364
0.377

Formulation
Code

pH

PL1

Korsmeyer–Peppas Model

3.2. Cytotoxicity Study
The cytotoxicity potential of CDDP@PLs was evaluated via an MTS assay in comparison with cisplatin solution against previously cultured MDA-MB-231 and SK-OV-3 cells.
The cells in 96-well plates were applied with cisplatin solution and CDDP@PLs and then
incubated for 24 h at 37 ◦ C. It was depicted from the cytotoxicity profile that CDDP@PLs
showed greater cytotoxicity as compared to cisplatin solution, indicating the improved
killing of the cells as compared to the cisplatin solution. The blank liposomes had no effect
on the cell cytotoxicity, indicating the biocompatibility of the liposomes. The CDDP@PLs
showed higher toxicity towards both cancer cell lines and decreased viability after 24 h
(Figure 5I) [44,45].
3.3. Cell Uptake Studies
A qualitative cellular uptake study was performed via confocal scanning laser microscopy (CSLM) to observe the colocalization of FITC-labeled CDDP@PLs, as shown in
Figure 5II). The cells were treated with DAPI; a blue color was observed in cells due to
nucleus staining with DAPI. Strong bright fluorescence was observed in cells treated with
FITC-labeled liposomes, while no fluorescence was observed in control. The presence of
green fluorescence confirmed the uptake of liposomes by the cells. CSLM was also used
to observe the binding and internalization of liposomes in MDA-MB-231 cell lines. DAPI
produces a blue color when interacting in cells, whereas FITC produces a green color after
interaction with the DNA of the cell. The improved internalization within the cells and
nuclei might be due to the presence of biocompatible lipids present in the liposomes. The
study performed by Chen, Y. et al., 2013, [46] also supports findings of the cellular uptake
study by the qualitative technique for DOPE pH-sensitive liposomes.
3.4. Stability Study
The stability of the CDDP@PLs was determined as shown in Table 3. The liposomal formulations were stored at different temperatures, i.e., 2–8 ◦ C, room temperature
(25 ± 2 ◦ C), and at elevated temperature (37 ± 2 ◦ C) for three months. After three months
of storage, the developed CDDP@PLs showed a slight increase in the particle size and PDI
and a decrease in the zeta potential. The particle size, PDI, and zeta potential showed no
significant difference at 2–8 ◦ C and room temperature (25 ± 2 ◦ C) (p < 0.05). However, there
was slight increase in the size, PDI and zeta potential at elevated temperature (37 ± 2 ◦ C),
which was due to the effect of elevated temperature on the phosphatidylethanolamine

3.2. Cytotoxicity Study
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The cytotoxicity potential of CDDP@PLs was evaluated via an MTS assay in
comparison with cisplatin solution against previously cultured MDA-MB-231 and SKOV-3 cells. The cells in 96-well plates were applied with cisplatin solution and CDDP@PLs
and then incubated for 24 h at 37 °C. It was depicted from the cytotoxicity profile that
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CDDP@PLs showed greater cytotoxicity as compared to cisplatin solution, indicating the
improved killing of the cells as compared to the cisplatin solution. The blank liposomes
had no effect on the cell cytotoxicity, indicating the biocompatibility of the liposomes. The
contents in showed
the liposomes.
stability
study
could
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of the
CDDP@PLs
higher The
toxicity
towards
both
cancer
cell lines and
decreased
viability
developed
CDDP@PLs
[22,29].
after 24 h (Figure 5I) [44,45].

Figure 5. (I) Cytotoxicity study of the cisplatin solution and CDDP@PLs on (a) MDA-MB-231 cells
and (b) SK-Ov-3 cells. Data are presented as mean ± SD (n = 3). ** p < 0.01, *** p < 0.001 and (II) cell
uptake of FITC by the MDA-MB-231 cell line.
Table 3. Stability study of CDDP@PLs at different temperature (after 3 months).
Formulation

Storage Condition

Time

Initial
PL1

◦C

2–8
25 ◦ C
37 ◦ C

After 90 days
Initial

PL2

◦C

2–8
25 ◦ C
37 ◦ C

After 90 days
Initial

PL3

◦C

2–8
25 ◦ C
37 ◦ C

After 90 days

Particle Size (nm)

PDI

Zeta Potential (mV)

206.4 ± 2.26

0.417 ± 0.008

−24.6 ± 1.72

209.5 ± 1.78
214.7 ± 2.45
219.8 ± 1.96

0.423 ± 0.004
0.441 ± 0.005
0.446 ± 0.003

−23.2 ± 1.07
−22.8 ± 0.86
−22.3 ± 1.01

194.3 ± 2.21

0.422 ± 0.010

−22.8 ± 2.01

197.1 ± 1.41
199.2 ± 0.97
204.7 ± 0.92

0.429 ± 0.011
0.434 ± 0.008
0.440 ± 0.005

−22.3 ± 0.61
−21.7 ± 0.70
−20.9 ± 1.40

191.2 ± 1.67

0.386 ± 0.009

−22.5 ± 0.38

196.3 ± 0.52
198.8 ± 1.41
201.4 ± 1.35

0.388 ± 0.004
0.391 ± 0.006
0.398 ± 0.013

−22.2 ± 1.87
−21.7 ± 0.56
−21.3 ± 1.02
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Table 3. Cont.
Formulation

Storage Condition

Time

Initial
PL4

◦C

2–8
25 ◦ C
37 ◦ C
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PL5

After 90 days
Initial

2–8 ◦ C
25 ◦ C
37 °C
37 ◦ C

After 90 days

Particle Size (nm)

PDI

Zeta Potential (mV)

171.9 ± 2.26

0.371 ± 0.011

−20.2 ± 2.69

173.6 ± 2.08
174.7 ± 1.15
182.9 ± 1.14

0.372 ± 0.007
0.376 ± 0.009
0.81 ± 0.013

−19.5 ± 1.63
−19.3 ± 2.07
−18.8 ± 0.91

153.2 ± 3.08

0.261 ± 0.007

−17.8 ± 1.26
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156.7 ± 1.85
0.264 ± 0.003
−17.3 ± 1.21
159.2 ± 2.92
0.267 ± 0.006
−16.5 ± 1.56
163.4 ±163.4
1.60± 1.60 0.273 ±0.273
0.010± 0.010 −16.2 ±−2.17
16.2 ± 2.17
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Table 4. Biochemical and hematological parameters of albino mice.

Biochemical Parameters
Bilirubin (mg/dL)
Urea (mg/dL)

Control Group
0.58 ± 0.09
35.45 ± 1.98

Test Group
0.61 ± 0.13
34.21 ± 2.34
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Table 4. Biochemical and hematological parameters of albino mice.
Biochemical Parameters

Control Group

Test Group

Bilirubin (mg/dL)
Urea (mg/dL)
Creatinine (mg/dL)
Uric acid (mg/dL)
Cholesterol (mg/dL)
Triglycerides (mg/dL)
ALT(IU/L)
Alkaline Phosphatase (IU/L)

0.58 ± 0.09
35.45 ± 1.98
0.19 ± 0.12
2.07 ± 0.45
59.87 ± 3.44
74.32 ± 1.34
69.55 ± 1.23
486.43 ± 4.59

0.61 ± 0.13
34.21 ± 2.34
0.23 ± 0.16
2.10 ± 0.39
61.22 ± 2.87
72.10 ± 1.65
70.98 ± 0.97
493.29 ± 4.11

Hematological Parameters

Control Group

Test Group

Red blood cells
White blood cells
Platelets
Lymphocytes
Monocytes
Neutrophils
Mean corpuscular volume (MCV)
Mean corpuscular hemoglobin
Hemoglobin (g/dL)

5.48 ± 0.67
7.67 ± 0.98
4.24 ± 0.59
61.42 ± 1.33
1.53 ± 1.90
44.32 ± 0.88
63.56 ± 0.61
21.33 ± 0.56
12.1 ± 0.35

5.21 ± 0.84
7.58 ± 0.77
4.21 ± 0.68
60.34 ± 1.19
1.49 ± 1.76
45.90 ± 0.93
62.87 ± 0.74
22.04 ± 0.43
12.5 ± 0.29

4. Conclusions
In the present study, CDDP@PLs were fabricated and evaluated for physicochemical
characterization, in vitro release profile, in vitro cytotoxicity, cell uptake study, stability
study and acute toxicity study. Our results advocate that cisplatin, when encapsulated
into pH-responsive liposomes, is effective in delivering drugs at tumor sites. Liposomes
with particle sizes lower than 200 nm facilitate higher drug concentrations in the tumor
microenvironment and poor lymphatic drainage by increasing the therapeutic effect via the
enhanced permeation and retention (EPR) effect. Mechanistically, the pH-responsive liposomes undergo rapid destabilization in an acidic environment and release the drug at the
tumor site. The neutral cone-shaped DOPE and weakly acidic amphiphile (CHEMS) were
used for the fabrication of CDDP@PLs due to their fusogenic behavior in the lipid bilayer.
Further, the developed CDDP@PLs will deliver the drug to the tumor neo-vascularization
due to small-sized liposomes, tumor-specific improved cytotoxicity, and enhanced cellular
internalization. The acute toxicity study performed in albino mice showed the safety and
biocompatibility of the developed pH-responsive carrier system. Finally, the developed
CDDP@PLs provide better tumor microenvironment responsive release faster at a pH of
5.5 than at a pH of 7.4 and 6.5, which provides a better perspective regarding a safe and
effective tumor-targeting lipid-vesicles-based drug delivery system that will maximize the
therapeutic effect and minimize the dose-related toxicity of cisplatin.
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